Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
REVIEW

Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia

Dorota M. Gertig A , Julia M. L. Brotherton A B and Marion Saville A
+ Author Affiliations
- Author Affiliations

A Victorian Cytology Service, PO Box 161, Carlton South, Vic. 3053, Australia.

B Corresponding author. Email: jbrother@vcs.org.au

Sexual Health 8(2) 171-178 https://doi.org/10.1071/SH10001
Submitted: 4 January 2010  Accepted: 21 May 2010   Published: 18 May 2011

Abstract

Accurate estimates of HPV vaccination coverage are critical for determining the proportion of the target female population that is not protected by the vaccine, as well as for monitoring the performance of vaccine delivery programs. The implementation of an HPV vaccination register, either as part of an existing immunisation register or stand-alone, can add substantial benefits to an HPV vaccination program. In Australia, the National HPV Vaccination Program Register supports the HPV vaccination program by providing information to consumers and providers about incomplete courses as well as estimates of vaccination coverage by age and area. Future monitoring of vaccine effectiveness will be facilitated by cross-linking to Pap test registries.

Additional keywords: genital warts, monitoring, papillomavirus.


Acknowledgements

We would like to acknowledge Genevieve Chappell, Karen Peasley and Lesley Rowlands for their work in preparation and provision of the coverage data for this report, and Penny Allen for administrative assistance. The NHVPR is fully funded by the Australian Government and operated by the Victorian Cytology Service Inc.


Addendum


Due to delays in obtaining government approval for release of coverage data from the NHVPR, coverage and program updates have occurred internationally since acceptance of this manuscript. The interested reader may therefore find the following references of supplementary interest:


Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. Report commissioned by UK Department of Health.


Centers for Disease Control and Prevention. National, State, and Local Area Vaccination Coverage among Adolescents Aged 13–17 Years – United States, 2009. MMWR Morb Mortal Wkly Rep 2009; 58: 997–1001.


Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current status of introduction of human papillomavirus vaccination in to national immunisation schedules in Europe: first results of the VENICE 2010 survey. Euro Surveill 2010: 15: pii–19730.


Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: Uptake, costs and issues for the National Health Insurance. Vaccine 2011, in press. doi:10.1016/j.vaccine.2011.02.064


References


[1] Brotherton JM. How much cervical cancer in Australia is vaccine preventable? A meta-analysis. Vaccine 2008; 26 250–6.
CrossRef | PubMed |

[2] International Agency for Research on Cancer/World Health Organization. IARC Handbooks of cancer prevention: cervix cancer screening. Lyon: IARC/WHO; 2005.

[3] Garland SM,  Steben M,  Sings HL,  James M,  Lu S,  Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009.;
CrossRef |

[4] Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 2007; 369 1861–8.
CrossRef | PubMed |

[5] Paavonen J,  Jenkins D,  Bosch FX,  Naud P,  Salmeron J,  Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369 2161–70.
CrossRef | CAS | PubMed |

[6] Paavonen J,  Naud P,  Salmeron J,  Wheeler CM,  Chow SN,  Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374 301–14.
CrossRef | CAS | PubMed |

[7] Wheeler CM,  Kjaer SK,  Sigurdsson K,  Iversen OE,  Hernandez-Avila M,  Perez G, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis 2009;
CrossRef |

[8] Bonanni P,  Boccalini S,  Bechini A. Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence. Vaccine 2009; 27(Suppl 1): A46–53.
CrossRef | CAS | PubMed |

[9] ECCA (European Cervical Cancer Association). HPV vaccination across Europe, 2009. Available online at: http://www.ecca.info [verified June 2010].

[10] Koulova A,  Tsui J,  Irwin K,  Van Damme P,  Biellik R,  Aguado MT. A brief report: country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine 2008; 26 6529–41.
CrossRef | PubMed |

[11] King LA,  Levy-Bruhl D,  O’Flanagan D,  Bacci S,  Lopalco PL,  Kudjawu Y, et al. Introduction of human papillomavirus (HPV) vaccination into national immunisation schedules in Europe: Results of the VENICE 2007 survey. Euro Surveill 2008; 7–9 13.


[12] Australian. Government, Department of Health. National immunisation program. Available online at: http://www.immunise.health.gov.au/ [verified June 2010].

[13] Fairbrother G,  Freed GL,  Thompson JW. Measuring immunization coverage. Am J Prev Med 2000; 19 78–88.
CrossRef | CAS | PubMed |

[14] Cuzick J,  Castanon A,  Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20–29 in the UK. Br J Cancer 2010; 102 933–9.
CrossRef | CAS | PubMed |

[15] Franco EL,  Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 2008; 26 A16–23.
CrossRef | PubMed |

[16] Franco EL,  Cuzick J,  Hildesheim A,  de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 2006; 24 S171–7.
CrossRef |

[17] Tota J,  Mahmud SM,  Ferenczy A,  Coutlée F,  Franco EL. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era. Sex Health 2010; 7 376–82.
CrossRef | PubMed |

[18] Dobson S , Dawar M , Scheifele D , Kollman T , McNeil S , Halperins S et al Are 2 doses of HPV vaccine adequate in girls? [conference abstract O-29.4]. 25th International Papillomavirus Conference Clinical & Educational Workshop, May 8–14 Malmo, Sweden; 2009.

[19] NHMRC. The Australian immunisation handbook 9th edition, 2008. Canberra: Australian Government; 2008.

[20] Department of Health and Ageing. Guidance on revaccination where HPV vaccine doses have been given at less than recommended minimum intervals. Canberra: Australian Government. Department of Health and Ageing; 2009. Available online at: http://immunise.health.gov.au/internet/immunise/publishing.nsf/Content/cmo-full-advice-hpv-cnt/$File/CMO-full-advice-hpv.pdf [verified June 2010].

[21] Ault KA. Long-term efficacy of human papillomavirus vaccination. Gynecol Oncol 2007; 107 S27–30.
CrossRef | CAS | PubMed |

[22] The National Health Amendment Act 2007. Canberra: Australian Government; 2007. Available online at: http://fedlaw.gov.au/ComLaw/Legislation/Act1.nsf/0/08C0837265607CA9CA2573FB00098717/$file/1352007.pdf [verified June 2010].

[23] Public summary document for quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, injection, 0.5 mL, Gardasil®. Canberra: Australian Government, Department of Health and Ageing. Available online at: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-gardasil-nov06 [verified November 2009].

[24] Hull BP,  Deeks SL,  McIntyre PB. The Australian Childhood Immunisation Register – a model for universal immunisation registers? Vaccine 2009; 27 5054–60.
CrossRef | PubMed |

[25] Young M , Morrell S , Harris W . Recruitment of women from a culturally and linguistically diverse background: Arabic, Cantonese, Mandarin, Korean and Spanish speaking women. NSW: NSW Cervical Screening Program & NSW Multicultural Health Communication Service; 2001.

[26] Taylor RJ,  Mamoon HA,  Morrell SL,  Wain GV. Cervical screening in migrants to Australia. Aust N Z J Public Health 2001; 25 55–61.
CrossRef | CAS | PubMed |

[27] Weber MF,  Banks E,  Smith DP,  O’Connell D,  Sitas F. Cancer screening among migrants in an Australian cohort; cross-sectional analyses from the 45 and Up study. BMC Public Health 2009; 9 144.
CrossRef | PubMed |

[28] HPV Vaccination Coverage. Statens Serum Institut-News-EPI NEWS No 6, 10/2/2010. Available online at: http://www.ssi.dk/English/News/EPI-NEWS/2010 [verified April 2011].

[29] HPV Vaccination Programme: Provisional data, as submitted by PCTs for First, Second and Third dose vaccine uptake, for the month ending 31 August, 2009. London: National Health Service. Available online at: http://www.immunisation.nhs.uk/publications/HPV_VaccineUptake_Aug2009.pdf [verified June 2010].

[30] Human Papillomavirus (HPV) Vaccine Uptake Annual Survey 2008/09. PCT Immunisation Coordinator User Guide for Determining the Annual Denominator and Vaccine Uptake of the ImFrom Website. Available online at: http://www.immunisation.nhs.uk/publications/HPV_AnnualReturnGuidance_acc.pdf [verified June 2010].

[31] NHS National Service. Child health. Childhood immunisations. Edinburgh: NHS National Service; 2010. Available online at: http://www.isdscotland.org/isd/5921.html [verified June 2010].

[32] Public Health Wales. Vaccine uptake in children in Wales October to December 2009. Public Health Cover Report. Public Health Wales, Vaccine Preventable Disease Programme and Communicable Disease Surveillance Centre. Available online at: http://www.wales.nhs.uk/sites3/Documents/457/Cov09q4%20%5Freport93.pdf [verified June 2010].

[33] Ministry of Health of Quebec. FlashVigie Bulletin Quebecois de vigie et d’entervention en maladie infectieuses, Vol. 4, No. 1, January 2009. Quebec: Ministry of Health; 2009.

[34] Colucci R,  Hryniuk W,  Savage C. Prevention: HPV Vaccination Programs in Canada. Report card on cancer in Canada, Winter 2008–2009. Cancer Advocacy Coalition of Canada 2008; 11 7–8.


[35] British Columbia Centre for Disease Control. Grades 6 and 9 female students who received the first dose of HPV vaccine, British Columbia. Available online at: http://www.bccdc.ca/NR/rdonlyres/0BE35108-CCBD-4DED-8EB8-62EA80213A21/0/EPI_Report_HPVPublicGrade6and9_Mar10_20100322.pdf [verified June 2010].

[36] Centers for Disease Control and Prevention National, state, and local area vaccination coverage among adolescents aged 13–17 years – United States, 2008. Morb Mortal Wkly Rep 2009; 58 997–1001.



Rent Article (via Deepdyve) Export Citation Cited By (50)